Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helga Gardarsdottir

Showing results (1-10 of 121) with videos related to

Pageof 13
Sort By:
Pharmacoepidemiology and Drug Safety|October 24, 2025
From Evidence to Impact: Closing the Loop in Pharmacovigilance With Real-World DataDaniel R Morales, Helga Gardarsdottir
Clinical Pharmacology and Therapeutics|July 12, 2024
Limitations Reported in Evaluating Effectiveness of Risk Minimization Measures in the EU during 2018-2021: A Qualitative Analysis of Industry-Sponsored Post-Authorization Safety StudiesRenske J Grupstra, Thomas Goedecke, Helga Gardarsdottir
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|November 13, 2020
Enabling appropriate use of antibiotics: review of European Union procedures of harmonising product information, 2007 to 2020Aleksandra Opalska, Marcel Kwa, Hubert Leufkens, et al.
Nederlands Tijdschrift Voor Geneeskunde|June 18, 2024
[Risk minimalisation measures for medications; are they incorporated in Dutch clinical guidelines?]Renske J Grupstra, Satu J Siiskonen, Helga Gardarsdottir
The Annals of Pharmacotherapy|October 14, 2010
The association between patient-reported drug taking and gaps and overlaps in antidepressant drug dispensingHelga Gardarsdottir, Toine C G Egberts, Eibert R Heerdink
Drug Safety|February 19, 2021
Assessing the Impact on Health of Pharmacovigilance Activities: Example of Four Safety SignalsFlorence van Hunsel, Laura Peters, Helga Gardarsdottir, et al.
Pharmacoepidemiology and Drug Safety|February 24, 2006
Potential bias in pharmacoepidemiological studies due to the length of the drug free period: a study on antidepressant drug use in adults in the NetherlandsHelga Gardarsdottir, Eibert R Heerdink, Antoine C G Egberts
British Journal of Clinical Pharmacology|August 2, 2019
Measuring the impact of pharmacovigilance activities, challenging but importantFlorence van Hunsel, Helga Gardarsdottir, Anthonius de Boer, et al.
American Journal of Epidemiology|June 6, 2009
Duration of antidepressant drug treatment and its influence on risk of relapse/recurrence: immortal and neglected time biasHelga Gardarsdottir, Toine C Egberts, Joost J Stolker, et al.
Clinical Pharmacology and Therapeutics|August 27, 2023
Review of Studies Evaluating Effectiveness of Risk Minimization Measures Assessed by the European Medicines Agency Between 2016 and 2021Renske J Grupstra, Thomas Goedecke, Jet Scheffers, et al.
Pageof 13

Showing results (1-10 of 121) with videos related to

Sort By:
Pageof 13
Pharmacoepidemiology and Drug Safety|October 24, 2025
From Evidence to Impact: Closing the Loop in Pharmacovigilance With Real-World DataDaniel R Morales, Helga Gardarsdottir
Clinical Pharmacology and Therapeutics|July 12, 2024
Limitations Reported in Evaluating Effectiveness of Risk Minimization Measures in the EU during 2018-2021: A Qualitative Analysis of Industry-Sponsored Post-Authorization Safety StudiesRenske J Grupstra, Thomas Goedecke, Helga Gardarsdottir
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|November 13, 2020
Enabling appropriate use of antibiotics: review of European Union procedures of harmonising product information, 2007 to 2020Aleksandra Opalska, Marcel Kwa, Hubert Leufkens, et al.
Nederlands Tijdschrift Voor Geneeskunde|June 18, 2024
[Risk minimalisation measures for medications; are they incorporated in Dutch clinical guidelines?]Renske J Grupstra, Satu J Siiskonen, Helga Gardarsdottir
The Annals of Pharmacotherapy|October 14, 2010
The association between patient-reported drug taking and gaps and overlaps in antidepressant drug dispensingHelga Gardarsdottir, Toine C G Egberts, Eibert R Heerdink
Drug Safety|February 19, 2021
Assessing the Impact on Health of Pharmacovigilance Activities: Example of Four Safety SignalsFlorence van Hunsel, Laura Peters, Helga Gardarsdottir, et al.
Pharmacoepidemiology and Drug Safety|February 24, 2006
Potential bias in pharmacoepidemiological studies due to the length of the drug free period: a study on antidepressant drug use in adults in the NetherlandsHelga Gardarsdottir, Eibert R Heerdink, Antoine C G Egberts
British Journal of Clinical Pharmacology|August 2, 2019
Measuring the impact of pharmacovigilance activities, challenging but importantFlorence van Hunsel, Helga Gardarsdottir, Anthonius de Boer, et al.
American Journal of Epidemiology|June 6, 2009
Duration of antidepressant drug treatment and its influence on risk of relapse/recurrence: immortal and neglected time biasHelga Gardarsdottir, Toine C Egberts, Joost J Stolker, et al.
Clinical Pharmacology and Therapeutics|August 27, 2023
Review of Studies Evaluating Effectiveness of Risk Minimization Measures Assessed by the European Medicines Agency Between 2016 and 2021Renske J Grupstra, Thomas Goedecke, Jet Scheffers, et al.
Pageof 13